All treatments proven to be effective for the treatment of congestive heart failure will be positively recommended (specifically ACE-inhibitors, betablockers, diuretics, digitalis, spironolactone).

Patients can be treated with amiodarone, aspirin and/or oral anticoagulants according to the clinical decision of attending investigators.

Open label n-3 PUFA or lipid lowering drugs are not permitted for patients in the R1 or R2 component of the trial, unless a specific clinical indication for treatment according to the Investigator judgment emerges during the course of the study.